🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

642 results for “Pharma Mar S.A.” Clear

  1. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Pharma Mar S.A.

    Breast Cancer

    phase 2 small molecule active

    1 trial

  2. EPI-7386, Xtandi - 40 mg soft capsules

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  3. Emrusolmin

    Pharma Mar S.A.

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  4. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Pharma Mar S.A.

    Parkinson's disease

    phase 2 other active

    1 trial

  5. Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension

    Pharma Mar S.A.

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  6. FLUOROURACIL , OXALIPLATIN , ABTL0812 Placebo, ABTL0812, IRINOTECAN , CALCIUM FOLINATE

    Pharma Mar S.A.

    Metastatic pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. Fancalen

    Pharma Mar S.A.

    Fanconi anemia (subtype A)

    phase 2 small molecule active

    1 trial

  8. G-STROPHANTHIN , The placebo vial contains NaCl 0.9% and phosphate buffer ad 1ml corresponding to the IMP except API for intravenous administration. There are no visible differences in comparison to volume, seize, exterior, colour etc. of the investigational product.

    Pharma Mar S.A.

    Acute Heart Failure

    phase 2 small molecule active

    1 trial

  9. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Pharma Mar S.A.

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  10. GR1014 Cutaneous Gel, The placebo ingredients are identical to those of GR1014-CG with the exception that the drug substance (amifostine) and hydrochloric acid (used at the hydrolysis step to convert amifostine in the active substance, amifostine thiol) are omitted.

    Pharma Mar S.A.

    Radiation-induced dermatitis (radiodermatitis)

    phase 2 small molecule active

    1 trial

  11. GTX-102, GTX/UX Diluent and Flush Solution

    Pharma Mar S.A.

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  12. Galvokimig, Placebo matching Test 0.9% sodium chloride solution for injection

    Pharma Mar S.A.

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  13. HDP-101

    Pharma Mar S.A.

    Relapsed or refractory Multiple Myeloma (r/r MM)

    phase 2 small molecule active

    1 trial

  14. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Pharma Mar S.A.

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  15. Humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody (mAb) targeting PAUF

    Pharma Mar S.A.

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. IDOR-1117-2520 matching placebo

    Pharma Mar S.A.

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  17. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Pharma Mar S.A.

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  18. INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  19. IPH6501

    Pharma Mar S.A.

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  20. IRINOTECAN, lurbinectedin

    Pharma Mar S.A.

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  21. Ilofotase alfa, Ilofotase alfa Placebo Drug Product

    Pharma Mar S.A.

    Risk for renal damage following open heart surgery

    phase 2 small molecule active

    1 trial

  22. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Pharma Mar S.A.

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  23. JAB-21822

    Pharma Mar S.A.

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  24. JTT-861, Placebo tablet for JTT-861

    Pharma Mar S.A.

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources